Sandoz Recalls Dicloxacillin Sodium Capsules Due to Impurity Testing Failures
Sandoz, Inc. is recalling Dicloxacillin Sodium Capsules because testing revealed out-of-specification results for a known impurity.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this as a Class III recall, which is defined as unlikely to cause adverse health consequences, aligning with the 'Low' severity criterion for documentation or minor specification issues.
Plain-English summary
Sandoz, Inc. is recalling Dicloxacillin Sodium Capsules, USP 250mg, 100 Capsule Bottle (NDC 0781-2248-01). The product was manufactured in Austria by Sandoz GmbH and distributed nationwide by Sandoz, Inc. in Princeton, NJ. The recall involves 78,606 bottles.
The recall was initiated due to failed impurities and degradation specifications. Specifically, testing obtained an out-of-specification result for a known impurity. The affected lots are EN3846 (Exp 08/2016), FA4809 (Exp 2/2017), and FW3654 (Exp 11/2017).
The FDA has classified this as a Class III recall. Consumers and healthcare providers should stop using the affected product and contact their healthcare provider or pharmacist for further instructions.
The recalled product
- Product
- Dicloxacillin Sodium Capsules, USP 250mg, Rx Only, 100 Capsule Bottle, Manufactured in Austria by Sandoz Gmbh, Distributed by Sandoz Inc., Princeton, NJ 08540, Product of Spain, NDC 0781-2248-01
- Manufacturer
- Sandoz, Inc
- Category
- Drug — Antibiotic
- Hazard
- Affected units
- 78,606
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot #s: EN3846
- Exp 08/2016
- FA4809
- Exp 2/2017
- FW3654
- Exp11/2017
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Sandoz, Inc under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same manufacturer · Sandoz, Inc
See all →- LowFocalin XR 5mg capsules carry incorrect or missing lot and expiry
FDA (Drugs) · 2026-06-24
- ModerateCyclophosphamide injection vials recalled after a transportation temperature excursion
FDA (Drugs) · 2025-09-24
- ModerateCiprofloxacin and dexamethasone otic suspension recalled following temperature abuse
FDA (Drugs) · 2025-09-17
- SevereBuffered penicillin G potassium vials may actually contain cefazolin for injection
FDA (Drugs) · 2025-07-09
- SevereSandoz cefazolin cartons contained vials labeled as penicillin G potassium
FDA (Drugs) · 2025-07-09
Same hazard · impurity
See all →- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 30mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17